Anika Therapeutics Inc. (ANIK)’s Financial Results Comparing With Vaxart Inc. (NASDAQ:VXRT)

As Biotechnology businesses, Anika Therapeutics Inc. (NASDAQ:ANIK) and Vaxart Inc. (NASDAQ:VXRT), are affected by contrast. This especially applies to their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anika Therapeutics Inc. 105.56M 4.03 18.72M 1.29 24.31
Vaxart Inc. 4.16M 2.82 18.35M -2.47 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Anika Therapeutics Inc. and Vaxart Inc.


Table 2 provides us Anika Therapeutics Inc. and Vaxart Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Anika Therapeutics Inc. 17.73% 7.3% 6.8%
Vaxart Inc. -441.11% -91% -40.7%

Risk & Volatility

Anika Therapeutics Inc. has a 1.42 beta, while its volatility is 42.00%, thus making it more volatile than Standard and Poor’s 500. Vaxart Inc. has a 0.58 beta and it is 42.00% less volatile than Standard and Poor’s 500.


The Current Ratio and a Quick Ratio of Anika Therapeutics Inc. are 18 and 16.1. Competitively, Vaxart Inc. has 2 and 2 for Current and Quick Ratio. Anika Therapeutics Inc.’s better ability to pay short and long-term obligations than Vaxart Inc.

Analyst Recommendations

The Ratings and Recommendations for Anika Therapeutics Inc. and Vaxart Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Anika Therapeutics Inc. 0 2 1 2.33
Vaxart Inc. 0 0 0 0.00

The upside potential is 29.07% for Anika Therapeutics Inc. with consensus target price of $38.67.

Insider and Institutional Ownership

Roughly 91.9% of Anika Therapeutics Inc. shares are held by institutional investors while 52.2% of Vaxart Inc. are owned by institutional investors. Anika Therapeutics Inc.’s share held by insiders are 0.5%. Insiders Comparatively, held 3.8% of Vaxart Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Anika Therapeutics Inc. -6.08% -17.5% -10.33% -24.28% -39.16% -6.75%
Vaxart Inc. -8.74% -18.54% -47.81% -45.6% -68.49% -11.17%

For the past year Anika Therapeutics Inc.’s stock price has smaller decline than Vaxart Inc.


On 12 of the 12 factors Anika Therapeutics Inc. beats Vaxart Inc.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The companyÂ’s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.